Induction with thymoglobuline, a potent anti-thymocyte polyclonal antibody, has been recently reported to allow minimization of postoperative immunosuppression in organ transplantation. The relationship with recurrence of hepatitis C virus (HCV) after liver transplantation (LTx) has never been investigated.We report here on the outcome in 22 HCV + patients receiving thymoglobuline pre-treatment and minimal immunosuppression after LTx.Patient survival and acute rejection rates were good, and remarkably low dosages and levels of immunosuppression were achieved with thymoglobuline, without exposing patients to an elevated risk of rejection. A progressive weaning of the primary immunosuppressor was also possible in the majority of patients without complications.The HCV recurrence rate was similar to what is reported in the literature, although lower HCV-RNA viral loads were obtained with thymoglobuline, with a mild histologic course.Although our results need to be validated in large cohort studies, our experience shows that minimization of immunosuppression with thymoglobuline is effective in protecting against rejection and demonstrated a positive impact on HCV recurrence that deserves further investigation. © Blackwell Munksgaard, 2005.

Induction with thymoglobuline, a potent anti-thymocyte polyclonal antibody, has been recently reported to allow minimization of postoperative immunosuppression in organ transplantation. The relationship with recurrence of hepatitis C virus (HCV) after liver transplantation (LTx) has never been investigated.We report here on the outcome in 22 HCV + patients receiving thymoglobuline pre-treatment and minimal immunosuppression after LTx.Patient survival and acute rejection rates were good, and remarkably low dosages and levels of immunosuppression were achieved with thymoglobuline, without exposing patients to an elevated risk of rejection. A progressive weaning of the primary immunosuppressor was also possible in the majority of patients without complications.The HCV recurrence rate was similar to what is reported in the literature, although lower HCV-RNA viral loads were obtained with thymoglobuline, with a mild histologic course.Although our results need to be validated in large cohort studies, our experience shows that minimization of immunosuppression with thymoglobuline is effective in protecting against rejection and demonstrated a positive impact on HCV recurrence that deserves further investigation. © Blackwell Munksgaard, 2005.

Minimization of immunosuppression with thymoglobuline pre-treatment and HCV recurrence in liver transplantation / De Ruvo, N.; Cucchetti, A.; Lauro, A.; Masetti, M.; Di Benedetto, F.; Cautero, N.; La Barba, G.; Dazzi, A.; Di Francesco, F.; Molteni, G.; Romano, A.; Ramacciato, G.; Risaliti, A.; Pinna, A. D.. - In: CLINICAL TRANSPLANTATION. - ISSN 0902-0063. - 19:2(2005), pp. 255-258. [10.1111/j.1399-0012.2005.00333.x]

Minimization of immunosuppression with thymoglobuline pre-treatment and HCV recurrence in liver transplantation

Lauro A.
Writing – Review & Editing
;
Ramacciato G.;
2005

Abstract

Induction with thymoglobuline, a potent anti-thymocyte polyclonal antibody, has been recently reported to allow minimization of postoperative immunosuppression in organ transplantation. The relationship with recurrence of hepatitis C virus (HCV) after liver transplantation (LTx) has never been investigated.We report here on the outcome in 22 HCV + patients receiving thymoglobuline pre-treatment and minimal immunosuppression after LTx.Patient survival and acute rejection rates were good, and remarkably low dosages and levels of immunosuppression were achieved with thymoglobuline, without exposing patients to an elevated risk of rejection. A progressive weaning of the primary immunosuppressor was also possible in the majority of patients without complications.The HCV recurrence rate was similar to what is reported in the literature, although lower HCV-RNA viral loads were obtained with thymoglobuline, with a mild histologic course.Although our results need to be validated in large cohort studies, our experience shows that minimization of immunosuppression with thymoglobuline is effective in protecting against rejection and demonstrated a positive impact on HCV recurrence that deserves further investigation. © Blackwell Munksgaard, 2005.
2005
Induction with thymoglobuline, a potent anti-thymocyte polyclonal antibody, has been recently reported to allow minimization of postoperative immunosuppression in organ transplantation. The relationship with recurrence of hepatitis C virus (HCV) after liver transplantation (LTx) has never been investigated.We report here on the outcome in 22 HCV + patients receiving thymoglobuline pre-treatment and minimal immunosuppression after LTx.Patient survival and acute rejection rates were good, and remarkably low dosages and levels of immunosuppression were achieved with thymoglobuline, without exposing patients to an elevated risk of rejection. A progressive weaning of the primary immunosuppressor was also possible in the majority of patients without complications.The HCV recurrence rate was similar to what is reported in the literature, although lower HCV-RNA viral loads were obtained with thymoglobuline, with a mild histologic course.Although our results need to be validated in large cohort studies, our experience shows that minimization of immunosuppression with thymoglobuline is effective in protecting against rejection and demonstrated a positive impact on HCV recurrence that deserves further investigation. © Blackwell Munksgaard, 2005.
HCV; Immunosuppression; liver transplantation; recurrence; tolerance; adult; aged; antilymphocyte serum; DNA, viral; follow-up studies; graft rejection; graft survival; hepacivirus; hepatitis C; humans; immunosuppression; immunosuppressive agents; methylprednisolone; middle aged; recurrence; survival rate; T-lymphocytes; tacrolimus; treatment outcome; viral load; liver transplantation; transplantation conditioning
01 Pubblicazione su rivista::01l Trial clinico
Minimization of immunosuppression with thymoglobuline pre-treatment and HCV recurrence in liver transplantation / De Ruvo, N.; Cucchetti, A.; Lauro, A.; Masetti, M.; Di Benedetto, F.; Cautero, N.; La Barba, G.; Dazzi, A.; Di Francesco, F.; Molteni, G.; Romano, A.; Ramacciato, G.; Risaliti, A.; Pinna, A. D.. - In: CLINICAL TRANSPLANTATION. - ISSN 0902-0063. - 19:2(2005), pp. 255-258. [10.1111/j.1399-0012.2005.00333.x]
File allegati a questo prodotto
File Dimensione Formato  
DeRuvo_Minimization_2005.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 89.8 kB
Formato Adobe PDF
89.8 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1547493
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 4
social impact